This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Explore conversion timing for a two-earner couple, including tax impact, income thresholds, and optimal years to convert for long-term growth.
17,865 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
A telecom stock this rose 19% over the past year, but a prominent fund sold out. Discover the drivers behind the move...
Geopolitics can push oil to $100 a barrel, but certain pipeline stocks thrive on throughput rather than price. Learn ...
China’s export engine and structural advantages are shaping a landscape where trade deals matter less than the decade...
When the Oscars fall silent on a beloved figure, families face more than grief—they face financial questions. This pi...
China is pivoting from selling finished goods to supplying key components for assembly abroad, fueling Southeast Asia...
Ukraine expands its drone-defense footprint in the Middle East, signaling a broader role for Kyiv as global markets w...
Markets move on news that the U.S. DEA has designated Colombia's president as a priority target in an ongoing probe. ...
Gold is leading gains in early 2026, while silver remains volatile. Analysts say the evolving ETF landscape is paving...
Waterfront properties can deliver strong returns, but they carry unique risks. This guide explains how to build solid...
Three months into 2026, the 2.8% COLA boosted average benefits to $2,071, but a surge in energy prices and Medicare w...
As traditional markets wobble, smart investors are turning to carefully chosen cryptocurrencies. This guide reveals t...